Active Pharmaceutical Ingredient: Definition & Manufacturing Guide

Comprehensive Guide to Active Pharmaceutical Ingredient (API)

In the modern pharmaceutical industry, the Active Pharmaceutical Ingredient serves as the core component of medicinal products, directly determining therapeutic efficacy and safety. Each year, over 5,000 chemical APIs enter production globally, with China as the world's largest API producer contributing more than 40% of the global market share. This article systematically analyzes the definition, manufacturing processes, regulatory certification systems, and quality control standards of Active Pharmaceutical Ingredients, providing comprehensive professional reference for pharmaceutical practitioners.

Overview of Active Pharmaceutical Ingredient

Definition and Core Functions

The Active Pharmaceutical Ingredient (API) refers to chemical substances with pharmacological activity in drugs that can directly produce therapeutic, preventive, or diagnostic effects on the body. Unlike excipients (such as starch, lactose, and other vehicles), the Active Pharmaceutical Ingredient is the critical substance determining drug efficacy. Examples include acetylsalicylic acid in aspirin and the β-lactam ring structure in penicillin, both of which are typical Active Pharmaceutical Ingredients. According to the World Health Organization (WHO) definition, qualified Active Pharmaceutical Ingredients must meet three basic requirements: chemical purity, stability, and biological activity.

Classification System: Sterile vs. Non-sterile APIs

Active Pharmaceutical Ingredients can be divided into two major categories based on production environment and quality requirements:

• Sterile APIs: Mainly used for dosage forms that directly enter the bloodstream or tissues, such as injections and ophthalmic preparations. Production must be completed in ISO 5 cleanrooms (Class 100), including products like penicillin sodium and insulin.
• Non-sterile APIs: Suitable for oral solid dosage forms (tablets, capsules), topical preparations, etc., with relatively lower production environment requirements (ISO 8), such as ibuprofen and metformin hydrochloride.

Additionally, APIs can be classified by source into chemically synthesized APIs, biologically fermented APIs, and naturally extracted APIs; by therapeutic area, they cover antibiotics, cardiovascular, anti-tumor, and other subcategories.

Key Differences from Finished Dosage Forms

The essential differences between Active Pharmaceutical Ingredients and finished dosage forms lie in functional positioning and manufacturing processes:

• Functional Differences: Active Pharmaceutical Ingredients are pure active substances that require formulation processes (such as granulation, tableting, coating) to become specific dosage forms suitable for safe patient use.
• Quality Control Focus: Active Pharmaceutical Ingredient testing focuses on chemical purity (e.g., impurity limits) and physicochemical properties (e.g., particle size distribution), while finished product testing emphasizes dissolution, bioavailability, and other in vivo performance indicators.
• Regulatory Management: In the EU market, Active Pharmaceutical Ingredients require separate CEP certification, while finished dosage forms need Marketing Authorization (MA) approval, each following different technical guidelines.

Manufacturing Processes for Active Pharmaceutical Ingredients

Chemical Synthesis Method

Chemical synthesis is currently the primary production method for Active Pharmaceutical Ingredients, accounting for over 65% of global production. This method converts basic chemical raw materials into target compounds through a series of chemical reactions (such as substitution, condensation, cyclization), offering advantages of high yield and controllable costs. The typical process includes:

1. Starting Material Preparation: Select starting materials meeting ICH Q7 standards and establish supplier audit systems
2. Reaction Stage: Construct molecular structures through multi-step chemical reactions, with critical process parameters (temperature, pressure, reaction time) validated through Design of Experiments (DoE)
3. Separation and Purification: Remove impurities using crystallization, chromatography, extraction, etc., typically requiring purity above 99.8%
4. Drying and Milling: Control moisture content (usually <0.5%) and particle size distribution (D90<100μm) to meet formulation requirements

Representative products: Paracetamol (acetaminophen), Atorvastatin calcium. Production processes must strictly control genotoxic impurities (such as nitrosamine compounds).

Biological Fermentation Technology

Biological fermentation technology is mainly used for producing antibiotics, vitamins, and other Active Pharmaceutical Ingredients, utilizing metabolic activities of microorganisms (bacteria, fungi) to synthesize target products. Compared with chemical synthesis, this method offers advantages of high selectivity and environmental friendliness but requires longer production cycles (typically 7-14 days).

Key technologies include:

• Strain Selection: Improve yield through genetic engineering modification, such as penicillin high-yield strains whose fermentation titer has increased from initial 20 units/ml to over 100,000 units/ml
• Fermentation Control: Adopt fed-batch processes with real-time monitoring of dissolved oxygen (DO), pH value, glucose concentration, and other parameters
• Downstream Processing: Separate bacterial cells from fermentation broth through filtration, centrifugation, ion exchange chromatography, then obtain high-purity Active Pharmaceutical Ingredients through purification
• Representative products: Penicillin G, Cephalosporin C, Vitamin B12. China holds 80% of the global market share in antibiotic Active Pharmaceutical Ingredients.

Natural Extraction and Semi-synthetic Processes

Natural extraction methods are suitable for obtaining active ingredients from plants, animals, or minerals, such as paclitaxel (extracted from Taxus) and artemisinin (extracted from Artemisia annua). With technological development, semi-synthetic processes have gradually become mainstream: parent compounds are first extracted from natural products, then chemically modified to optimize their pharmacological properties.

Typical cases include:

• Steroid Hormone APIs: Using diosgenin (extracted from Dioscorea) as starting material to synthesize prednisolone through oxidation, epoxidation, and other reactions
• Semi-synthetic Antibiotics: Using 6-APA (penicillin cleavage product) as the mother nucleus to prepare amoxicillin, ampicillin, and other broad-spectrum penicillins through acylation reactions
• Alkaloid Drugs: Extract ephedrine from Ephedra sinica and obtain dextromethorphan through chiral resolution

Challenges of this process include unstable raw material sources and low extraction efficiency. In recent years, plant cell culture technology (such as shikonin bioreactors) has gradually been applied in industrial production.

International Regulations and Certification Systems

CEP/COS Certification (European Market)

CEP (Certificate of Suitability) certification, formerly known as COS (Certificate of Suitability to the Monographs of the European Pharmacopoeia), is the compliance certification for Active Pharmaceutical Ingredients by the European Medicines Agency (EMA).

Its core requirements include:

• Scope of Application: All Active Pharmaceutical Ingredients used in medicinal products marketed in Europe must comply with European Pharmacopoeia (EP) monograph requirements
• Technical Documentation: Complete quality data must be submitted, including manufacturing process descriptions, impurity profile analysis, stability studies, etc.
• On-site Inspection: EMA may initiate unannounced inspections based on risk levels, focusing on critical process steps and quality control measures
• Validity Period: Certificates are permanently valid but must be updated promptly when EP is revised (usually March and September annually)

Compared with EDQM (European Directorate for the Quality of Medicines) cooperation procedures, CEP certification offers mutual recognition advantages and is recognized by 38 European countries as well as Turkey, Russia, etc. As of 2024, Chinese enterprises have obtained over 1,200 CEP certificates, accounting for 28% of the global total.

FDA and DMF Documentation (US Market)

The US FDA requires submission of Drug Master Files (DMF) for imported Active Pharmaceutical Ingredients, which are categorized as follows:

• Type II DMF: The most common type, containing manufacturing processes, quality control, stability, and other data for Active Pharmaceutical Ingredients
• Submission Process: Submitted through FDA's electronic portal (ESG), must comply with eCTD format requirements, with a review cycle of approximately 180 days
• Associated Approval: DMFs are not approved independently but require associated review with New Drug Applications (NDA) or Abbreviated New Drug Applications (ANDA) for finished products
• On-site Inspection: FDA conducts Pre-Approval Inspections (PAI) to inspect production facilities, focusing on data integrity and process control

Notably, the FDA's 2023 "Quality Systems for API" guidance strengthened requirements for lifecycle management of Active Pharmaceutical Ingredients, adding specific provisions for continuous process verification and change control.

Chinese GMP Certification Requirements

China's National Medical Products Administration (NMPA) implements GMP (Good Manufacturing Practice) certification for Active Pharmaceutical Ingredient production.

The 2020 GMP Appendix "Active Pharmaceutical Ingredients" clearly stipulates:

• Cleanliness Requirements: Purification, drying, and packaging processes for non-sterile APIs should be conducted in Grade D cleanrooms; sterile APIs require Grade A conditions within Grade B backgrounds
• Quality Risk Management: Must use FMEA (Failure Mode and Effects Analysis) tools from ICH Q9 guidelines to identify production risks
• Data Management: Electronic data must comply with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate)
• Annual Reporting: After certification, annual quality review reports must be submitted, including product quality trends, deviation handling, change control, etc.

Progress has been made in mutual recognition between Chinese GMP and international standards. Currently, mutual recognition agreements have been reached with WHO and EU, allowing Active Pharmaceutical Ingredients certified by Chinese GMP to directly enter multiple emerging markets.

Quality Control Standards

Pharmacopoeia Comparison (USP/EP/BP/CP)

Major pharmacopoeias have different standard requirements for Active Pharmaceutical Ingredients, with key comparisons as follows:

For example, for amoxicillin Active Pharmaceutical Ingredient, USP requires related substance A not to exceed 0.3%, while EP requires individual unknown impurities not to exceed 0.1%, reflecting stricter quality control standards in the European market.

Special Testing Requirements for Sterile APIs

Sterile Active Pharmaceutical Ingredients require additional key testing:

• Sterility Testing: Conduct microbial limit testing according to pharmacopoeial methods, requiring negative results from both membrane filtration and direct inoculation methods
• Bacterial Endotoxin Testing: Use Limulus Amebocyte Lysate (LAL) method, controlling endotoxin content <0.25 EU/mg (adjusted based on route of administration)
• Particulate Contamination: For 5μm and 10μm particle sizes, the number of particles per gram of API must not exceed 6,000 and 600 respectively
• Moisture Determination: Use Karl Fischer method, typically requiring moisture <0.5%, with freeze-dried products allowed up to 3.0%
• Container Closure Integrity Testing: Packaging containers must pass dye penetration or vacuum decay testing to ensure sterility during storage

These tests must be conducted in ISO 7 clean laboratories, with testing personnel requiring regular sterile technique training and qualification verification.

Stability Studies and Shelf-life Determination

Stability studies for Active Pharmaceutical Ingredients follow ICH Q1A guidelines, determining shelf-life through accelerated and long-term testing:

• Long-term Testing: Storage at 25℃±2℃/60%RH±5%RH for 12 months, sampling and testing every 3 months
• Accelerated Testing: Storage at 40℃±2℃/75%RH±5%RH for 6 months to evaluate degradation trends
• Intermediate Conditions: When significant degradation occurs in accelerated testing, supplementary testing at 30℃±2℃/65%RH±5%RH is required
• Stability Indicators: Focus on monitoring key quality attributes such as assay, related substances, moisture, pH value

According to ICH Q1E guidelines, shelf-life can be appropriately extended through statistical analysis but requires sufficient supporting data. For example, a cephalosporin Active Pharmaceutical Ingredient maintaining 98.5% assay after 12 months in long-term testing could have its shelf-life extended from 2 years to 3 years.

Conclusion

As the cornerstone of the pharmaceutical industry, the quality and innovation of Active Pharmaceutical Ingredients directly relate to drug accessibility and patient safety. With increasingly stringent regulatory requirements and accelerated technological innovation, the industry is moving toward greater efficiency and sustainability. For pharmaceutical companies, in-depth understanding of Active Pharmaceutical Ingredient manufacturing processes, regulatory frameworks, and quality standards will be crucial for success in global competition. In the future, we can reasonably expect that with the maturity of continuous manufacturing, biological manufacturing, and other technologies, the Active Pharmaceutical Ingredient industry will make greater contributions to global health initiatives.

For high-quality pharmaceutical raw materials and active pharmaceutical ingredients, trust Sinoright. With our extensive experience in API manufacturing and strict quality control systems, we provide reliable supply chain solutions to pharmaceutical companies worldwide. Contact us today for your specific requirements.

Contact now